About OraSure Technologies
OraSure Technologies (NASDAQ:OSUR) specializes in the development, manufacture, and distribution of diagnostic tests and sample collection devices. The company focuses on providing products for the detection of infectious diseases and the collection, stabilization, and transport of biological samples. OraSure aims to improve health outcomes by providing quick, accurate, and accessible diagnostic solutions for conditions such as HIV, hepatitis C, and Ebola, as well as for genomics and microbiome applications. Their product range also supports the growing needs of the molecular diagnostics field, including solutions for COVID-19 testing. With a commitment to innovation, OraSure continually strives to expand its product offerings and global reach, aiming to meet the evolving health diagnostics and sample collection needs of both the healthcare sector and consumers directly.
Snapshot
Operations
Products and/or services of OraSure Technologies
- The OraQuick In-Home HIV Test, the first FDA-approved in-home HIV test allowing self-testing without the need for a laboratory.
- Intercept Oral Fluid Drug Test, a lab-based oral fluid drug test providing an easy and non-invasive method of drug screening.
- Oragene DNA Self-Collection Kit, designed for easy, non-invasive collection of DNA from saliva for genomic and genetic testing.
- Q.E.D. Saliva Alcohol Test, a rapid, on-site alcohol test providing results in minutes, approved by the U.S. Department of Transportation.
- Genotek Microbiome and Virology collection kits, facilitating the collection, stabilization, and transport of DNA and RNA from viruses and bacterial communities for research.
- Diversigen, offering comprehensive microbiome and metagenomics services for accelerating research and development in the pharmaceutical and academic sectors.
OraSure Technologies executive team
- Ms. Carrie Eglinton MannerPresident, CEO & Director
- Mr. Kenneth J. McGrathChief Financial Officer
- Ms. Michele AnthonySenior VP, Chief Accounting Officer, Controller & Assistant Secretary
- Ms. Karen DaviesDiagnostics R&D & Chief Technologist
- Mr. Rafal Iwasiow Ph.D.Sample Management Solutions R&D & Chief Scientist
- Mr. Jason Michael PlagmanVice President of Investor Relations
- Mr. Stefano TaucerGeneral Counsel & Corporate Secretary
- Mr. David A. Rappaport C.F.A.Senior Vice President of Corporate Development, Strategy & Integration
- Ms. Amy SteigerwaltSenior Vice President of Human Resources
- Mr. Zachary WertSenior Vice President of Global Operations